418 related articles for article (PubMed ID: 25596034)
1. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
2. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
3. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
4. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
6. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma.
Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
[TBL] [Abstract][Full Text] [Related]
9. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
11. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.
Kushner BH; O'Reilly RJ; LaQuaglia M; Cheung NK
Cancer; 1990 Sep; 66(6):1095-100. PubMed ID: 2400963
[TBL] [Abstract][Full Text] [Related]
13. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Med Pediatr Oncol; 2003 Dec; 41(6):508-15. PubMed ID: 14595707
[TBL] [Abstract][Full Text] [Related]
15. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
[TBL] [Abstract][Full Text] [Related]
16. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
17. Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group.
Cohen BH; Geyer JR; Miller DC; Curran JG; Zhou T; Holmes E; Ingles SA; Dunkel IJ; Hilden J; Packer RJ; Pollack IF; Gajjar A; Finlay JL;
Pediatr Neurol; 2015 Jul; 53(1):31-46. PubMed ID: 26092413
[TBL] [Abstract][Full Text] [Related]
18. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
[TBL] [Abstract][Full Text] [Related]
20. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
